Apr . 24, 2026 14:02 Kembali ke daftar
Human Papillomavirus (HPV) infection is widely recognized as one of the primary causes of cervical cancer, which remains a leading threat to women’s health worldwide. Persistent infection with high-risk HPV (HR-HPV) types, particularly HPV 16 and HPV 18, is strongly associated with the development of cervical intraepithelial neoplasia and malignant transformation. Therefore, early and accurate detection of high-risk HPV is essential for effective screening, prevention, and clinical intervention.
Itu Kit Deteksi HPV Cowingene (2+16) (Cair) is an advanced in vitro diagnostic (IVD) solution designed for the qualitative detection of HPV DNA using real-time PCR technology. The kit enables simultaneous detection of 18 high-risk HPV types in a single assay, while specifically genotyping HPV 16 and HPV 18, providing critical clinical insights for risk stratification and patient management.

This detection kit is intended for the qualitative detection of HPV DNA in human clinical specimens. It supports the identification of:
HPV 16 and HPV 18 (individually typed)
16 additional high-risk HPV types, including:
26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, and 82
By combining specific genotyping (16/18) with broad-spectrum high-risk screening, the kit provides a balanced approach to HPV detection—allowing clinicians to identify both the most oncogenic types and other clinically relevant high-risk infections.
The results serve as important auxiliary evidence for cervical cancer screening, early diagnosis, and follow-up monitoring, supporting healthcare providers in making informed clinical decisions.
The kit is validated for use with the following specimen types:
Urine samples
Cervical swabs
This flexibility enables both clinician-collected and self-collected sampling approaches, improving patient compliance and expanding access to screening programs. Urine-based testing also offers a non-invasive alternative, making it particularly suitable for large-scale population screening.
The kit demonstrates an analytical sensitivity (LoD) of 100 copies/mL, allowing detection of very low levels of HPV DNA. This is critical for identifying early-stage infections before clinical symptoms or cytological abnormalities appear.
Extensive validation shows that the kit has no cross-reactivity with non-target pathogens commonly found in the reproductive tract, including:
Chlamydia trachomatis
Neisseria gonorrhoeae
Candida albicans
Trichomonas vaginalis
Gardnerella vaginalis
Ureaplasma species and other HPV types not included in the panel
This ensures highly accurate detection and minimizes false-positive results.
The assay performance is not affected by common interfering substances such as:
Hemoglobin
White blood cells
Cervical mucus
Vaginal care products and lubricants
Antibiotics such as metronidazole
This robustness reflects real clinical sample conditions and enhances test reliability.
Detection of HPV 16, HPV 18, and the other 16 high-risk types does not interfere with each other, ensuring accurate multiplex detection across all channels.
The kit demonstrates excellent precision, with coefficient of variation (CV ≤ 5%) across:
Different days (intra/inter-day)
Different batches
Different operators and testing sites
Detection Method: Multiplex real-time PCR
Detection Channels: FAM, VIC/HEX, ROX, CY5
Detection Coverage: 18 high-risk HPV types
Compatible Instruments:
ABI 7500
Roche LightCycler 480
Bio-Rad CFX96
Other open PCR systems
Storage Conditions: ≤ -20°C
Shelf Life: 18 months
Certification: CE-IVD
These specifications ensure compatibility with mainstream laboratory equipment and support seamless workflow integration.
The liquid-based format offers several advantages in molecular diagnostics:
Improved sample preservation, maintaining nucleic acid integrity
Reduced pre-analytical variability, ensuring consistent results
Better compatibility with automated systems, supporting high-throughput testing
Streamlined workflow, reducing manual handling and operational errors
This makes the kit particularly suitable for hospitals, diagnostic laboratories, and large-scale screening programs.
The kit can be integrated into a standardized diagnostic workflow using recommended supporting reagents:
DNA/RNA extraction kits
Sample release reagents
Self-collection kits (urine and vaginal)
This enables efficient processing from sample collection to final result, improving laboratory productivity and consistency.
18-in-1 high-risk HPV detection in a single test
Specific genotyping of HPV 16 and 18 for risk stratification
Ultra-high sensitivity (LoD 100 copies/mL) for early detection
Multiple sample compatibility, including non-invasive urine samples
Strong specificity and anti-interference performance
No cross-reaction or competitive interference
Compatible with mainstream PCR platforms
CE-IVD certified, ensuring quality and compliance
The Cowingene HPV (2+16) Detection Kit (Liquid) provides a comprehensive, accurate, and efficient molecular diagnostic solution for high-risk HPV detection. By combining multiplex PCR technology with high analytical sensitivity and flexible sampling options, it significantly enhances early screening capabilities for cervical cancer prevention.
This kit not only improves diagnostic accuracy but also supports large-scale screening programs and early intervention strategies, ultimately contributing to better patient outcomes and reduced disease burden.
As global demand for precise and scalable diagnostic solutions continues to grow, the Cowingene HPV (2+16) Detection Kit stands out as a reliable tool for modern molecular laboratories and women’s health management.
Terkait PRODUK
Rapid HPV 16/18/45 Molecular Detection with NATBox for Targeted Cervical Cancer Screening
BeritaApr.24,2026Comprehensive HPV 28 Genotyping Solution for Advanced Cervical Cancer Screening
BeritaApr.24,2026Comprehensive HPV 15 Genotyping Solution for Accurate Cervical Cancer Risk Assessment
BeritaApr.24,2026Comprehensive 14-Pathogen STI Detection Solution for Accurate Molecular Diagnosis
BeritaApr.24,2026Accurate and Reliable HSV-1/2 Molecular Detection for Clinical Diagnosis
BeritaApr.24,2026